Related Experiment Videos
Cryoglobulinemia in hepatitis C virus chronic active hepatitis: effects of interferon-alpha therapy
M Casaril1, F Capra, G B Gabrielli
1Institute of Medical Pathology, University of Verona, Italy.
Insights
Hepatitis C virus (HCV) infection is linked to mixed cryoglobulinemia (MC). Interferon-alpha (IFN-alpha) treatment cleared MC in responders, correlating with HCV RNA clearance.
Area of Science:
- Hepatology
- Immunology
- Virology
Background:
- Chronic hepatitis C virus (HCV) infection is associated with various extrahepatic manifestations.
- Mixed cryoglobulinemia (MC) is a known complication, affecting a significant portion of HCV patients.
- Understanding MC prevalence and treatment response is crucial for managing HCV complications.
Purpose of the Study:
- To determine the prevalence of MC in chronic HCV patients.
- To evaluate the efficacy of interferon-alpha (IFN-alpha) in treating MC.
- To explore the relationship between MC clearance, HCV RNA clearance, and treatment response.
Main Methods:
- Prospective study of 100 chronic HCV patients.
- Detection and characterization of cryoglobulins at baseline.
- Treatment with IFN-alpha (6 MU thrice weekly) for 6 months.
- Assessment of treatment response based on aminotransferase levels and cryoglobulinemia status.
Main Results:
- MC was detected in 36% of patients at admission, with an additional 18% developing it during observation.
- Patients with MC were older and had a higher incidence of cirrhosis.
- IFN-alpha treatment led to MC disappearance in 11 of 21 evaluable responders, but none of the non-responders (p < 0.003).
- MC clearance was consistently associated with HCV RNA clearance.
Conclusions:
- MC is a common finding in chronic HCV infection.
- IFN-alpha treatment can lead to the resolution of MC in a subset of responders.
- Clearance of MC during treatment is linked to viral clearance and may predict relapse risk.
Abstract:
We investigated the prevalence of mixed cryoglobulinemia (MC) in 100 cases of chronic hepatitis C virus (HCV) infection and the effect of a 6-month treatment with interferon-alpha (IFN-alpha). Cryoglobulins were detected on admission in 36 of 100 patients and appeared during observation in a further 18 cases. Cryocrit ranged from 0.5% to 20%. Patients with MC were older and had a higher incidence of cirrhosis than those without MC. Immunologic characterization of the cryoprecipitate showed the presence of type II in 84% of cases and type III in 16%. The patients received IFN-alpha (6 MU three times per week) for 6 months. Fifty-seven were responders (i.e., reached normal aminotransferase levels), 26 of these relapsed within 2 months after IFN withdrawal, and 30 did not relapse. After IFN-alpha treatment, cryoglobulinemia disappeared in 11 of the 21 evaluable responders, but in none of the 15 nonresponder patients (p < 0.003). The clearance of MC was associated in all cases with clearance of HCV RNA. The delayed appearance of cryoglobulinemia in responders seems to be associated with a higher probability of relapse.